P580 Biologic therapy in pregnancy and inflammatory bowel disease: a prospective 7 year study: clinical outcome

Published on Feb 1, 2013in Journal of Crohn's and Colitis8.658
· DOI :10.1016/S1873-9946(13)60601-7
F. Habal1
Estimated H-index: 1
Sources
Abstract
📖 Papers frequently viewed together
References0
Newest
Cited By7
Newest
#1Kristel Leung (U of T: University of Toronto)H-Index: 4
#2Parul Tandon (U of T: University of Toronto)H-Index: 12
Last. Vivian Huang (U of T: University of Toronto)H-Index: 19
view all 5 authors...
BACKGROUND Patients with inflammatory bowel disease (IBD) may be at increased risk of adverse neonatal outcomes. The aim of this study was to determine pooled incidences and risk factors for these outcomes. METHODS Medline, Embase, and Cochrane Library were searched through May 2019 for studies reporting adverse neonatal outcomes in IBD. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS The pooled incidence of preterm birth, low birth weight, congenital anomalies, an...
7 CitationsSource
#1Ole Haagen Nielsen (UCPH: University of Copenhagen)H-Index: 77
#2John Gubatan (Stanford University)H-Index: 10
Last. Cynthia Maxwell (U of T: University of Toronto)H-Index: 23
view all 5 authors...
Abstract Background & Aims Biologics are routinely used in pregnant women with inflammatory bowel disease (IBD) but large-scale data reporting adverse pregnancy outcomes among biologic users are lacking. We sought to estimate the prevalence of adverse pregnancy outcomes in women with IBD on biologic therapies. Methods We searched major databases from inception to June 2020 for studies estimating the prevalence of adverse pregnancy outcomes in IBD when using biologics (anti-TNF, anti-integrins, a...
11 CitationsSource
#1Parul Tandon (U of T: University of Toronto)H-Index: 12
#2Vivek Govardhanam (U of T: University of Toronto)H-Index: 2
Last. Vivian Huang (U of T: University of Toronto)H-Index: 19
view all 5 authors...
BACKGROUND: The effect of inflammatory bowel disease (IBD) on pregnancy-related outcomes remains unknown. AIM: To determine the risk of adverse maternal, placental and obstetric outcomes in IBD METHODS: We searched Medline, Embase and Cochrane library through May 2019 for studies reporting adverse maternal, placental and obstetric outcomes in patients with IBD. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for these outcomes in patients with IBD compared to healthy controls...
13 CitationsSource
#1Zaid Shihab (University of Melbourne)H-Index: 1
#2Neville D. Yeomans (University of Melbourne)H-Index: 43
Last. Peter De CruzH-Index: 20
view all 3 authors...
Background and Aims: Inflammatory Bowel Disease (IBD) commonly affects women during their reproductive years leading to concerns regarding pregnancy outcomes and therapeutic safety. The aim of this study was to assess the risks associated with anti-Tumour Necrosis Factor α (anti-TNFα) therapy treatment on pregnancy outcomes including rates of congenital abnormality based on published studies. Methods: Published studies were screened from on-line databases and international meeting abstracts. A m...
46 CitationsSource
#1Neeraj Narula (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 23
Last. John Marshall (McMaster University)H-Index: 89
view all 5 authors...
BACKGROUND: The use of TNFα antagonists is well described for inflammatory bowel disease (IBD), but their safety profile during pregnancy is yet to be fully elucidated. A systematic review and meta-analysis were performed to identify studies that explored the safety of anti-TNFα therapy during pregnancy in patients with IBD. METHODS: A systematic literature search was conducted to identify studies that investigated the pregnancy outcomes among women with IBD on anti-TNFα therapy. The primary out...
59 CitationsSource
#1Ole Haagen Nielsen (UCPH: University of Copenhagen)H-Index: 77
#2Edward V. Loftus (Mayo Clinic)H-Index: 114
Last. Tine JessH-Index: 55
view all 3 authors...
Background Tumor necrosis factor (TNF)-α inhibitors are increasingly being used in inflammatory bowel disease (IBD). Because this chronic intestinal disorder often affects women of fertile age, it is essential to assess the effect of biologics on pregnancy outcome.
97 CitationsSource